Dr. Vollrath is an experienced life-science executive and has been with Amprion for over six years. Previously, Dr. Vollrath was CEO of Xetrios Therapeutics, a biotechnology company focused on novel therapeutics for autommune diseases and cancer, which was acquired by Kolltan Pharmaceuticals. Earlier in his career, Dr. Vollrath spent four years as Entrepreneur in Residence at Avalon Ventures, a San Diego-based Venture Capital firm focused on developing early-stage life science companies. During his tenure with Avalon Ventures, Dr. Vollrath was a co-founder and senior member of the management teams of several biotech companies, including Afraxis (focused on CNS therapeutics, acquired by Genentech for $187M), Carolus Therapeutics and Otonomy (NASDAQ: OTIC). Prior to Avalon, Dr. Vollrath was a Scientist at Renovis, a San Francisco-based CNS drug discovery company, and Merck. Dr. Vollrath is Principal Investigator on several Small Business Technology Transfer grant applications funded by the NIH.